axicabtagene ciloleucel

Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021

Shots: The P-II ZUMA-5 trial assessing Yescarta in 146 patients aged ≥18rs. with r/r iNHL include FL, prior treated with at least 2L of systemic therapy Results: 94% of patients achieved a response @18mos., & 2EPs of mPFS and OS were not yet reached. In a weighted analysis, the results compared with ZUMA-5 patients vs …

Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021 Read More »